SOUTHERN ARIZONA CLINICAL TRIALS

SOUTHERN ARIZONA CLINICAL TRIALS
Breast Cancer
Veliparib ABT-888 Neoadj TNBC
Brentuximab Vedotin in Older Pts with HL
USON 12152: A Randomized, Placebo-Controlled, DoubleBlind, Phase III Study Evaluating Safety and Efficacy of the
Addition of Veliparib Plus Carboplatin Versus the Addition of
Carboplatin to Standard Neoadjuvant Chemotherapy Versus
Standard Neoadjuvant Chemotherapy in Subjects with Early
Stage Triple Negative Breast Cancer
USON 11282: A Phase II Open-Label Study of Brentuximab
Vedotin in Front-Line Therapy of Hodgkin lymphoma (HL) in
Adults Age 60 and Above
Niraparib vs PhyChoice HER2-gBRCA Breast
USON 13112: A Phase III, Randomized, Open Label,
Multicenter, Controlled Trial of Niraparib Versus Physician’s
Choice in Previously-Treated, Her2 Negative, Germline BRCA
Mutation-Positive Breast Cancer Patients
Gynecologic Cancer
Trabectedin +/- PLD adv Ovarian 2/ 3 ln
USON 12232: A Randomized, Open-Label Study Comparing
the Combination of YONDELIS® and DOXIL®/CAELYX®
With DOXIL®/CAELYX® Monotherapy for the Treatment of
Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or
Fallopian Tube Cancer
Leukemia & Lymphoma
Rev+Ritux, R/R FL, MZL, MCL
USON 13064: A Phase IIIB Randomized Study of Lenalidomide
Plus Rituximab Maintenance Therapy Followed by
Lenalidomide Single-Agent Maintenance Versus Rituximab
Maintenance in Subjects with Relapsed/Refractory Follicular,
Marginal Zone or Mantle Cell Lymphoma
Idela + Ritux, 1Ln CLL, 17p Del
USON 13142: A Phase II, Single Arm Study Evaluating
the Efficacy and Safety of Idelalisib in Combination with
Rituximab in Patients with Previously Untreated Chronic
Lymphocytic Leukemia with 17p Deletion
GS-9973 (Syk Inh) in R/R Heme Malig
USON 12154: A Phase 2, Open-Label Study Evaluating the
Efficacy, Safety, Tolerability, and Pharmacodynamics of GS9973 in Subjects with Relapsed or Refractory Hematologic
Malignancies
For more information or to refer a patient,
call 855-880-CURE.
Trial listing current as of 3/2015.
Melanoma
LGX818 +/- MEK162 v Vem Melanoma
USON 13079: A Phase III Randomized, 3-Arm, Open Label,
Multicenter Study of LGX818 plus MEK162 and LGX818
Monotherapy Compared with Vemurafenib in Patients with
Unresectable or Metastatic BRAF V600 Mutant Melanoma
Ovarian Cancer
Maint Niraparib PlatSensOvarian
USON 13008: A Phase III Randomized Double-Blind Trial of
Maintenance with Niraparib Versus Placebo in Patients with
Platinum Sensitive Ovarian Cancer
Gem/Carbo+LY2228820 2Ln plat sen OvCa
USON 10312: A Randomized, Double-Blind, PlaceboControlled Phase Ib/II Study of LY2228820, a p38 MAPK
Inhibitor, plus Gemcitabine and Carboplatin versus
Gemcitabine and Carboplatin for Women with PlatinumSensitive Ovarian Cancer
Pancreatic Cancer
PEGPH20+Nab+Gem Stage IV Pancr
USON 12237: A Phase II, Randomized, Multicenter Study of
PEGPH20 (PEGylated Recombinant Human Hyaluronidase)
Combined with nab-Paclitaxel Plus Gemcitabine Compared
With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage
IV Previously Untreated Pancreatic Cancer
Ph3 Jak Inhibitor w Cape for mPC
USON 13197: A Randomized, Double-Blind, Phase III Study of
the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination
with Capecitabine in Subjects with Advanced or Metastatic
Adenocarcinoma of the Pancreas Who Have Failed or are
Intolerant to First-Line Chemotherapy
Prostate Cancer
Renal Cancer
DCVAC/PCa +SOC v Placebo in metCRP
Axitinib +/- Dalantercept Adv RCC
USON 13024: A Randomized, Double Blind, Multicenter,
Parallel-Group, Phase III Study to Evaluate Efficacy and
Safety of DCVAC/PCa Versus Placebo in Men with Metastatic
Castration Resistant Prostate Cancer Eligible for 1st Line
Chemotherapy
USON 14091: A Phase II Randomized, Double-Blind Study of
Dalantercept plus Axitinib Compared to Placebo plus Axitinib
in Patients with Advanced Renal Cell Carcinoma
RADIATION CLINICAL TRIALS
Breast Cancer
Prostate Cancer
Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo
STAD w/ Pelvic LN or Prostate RT
USON 13091: A Randomized Phase III Clinical Trial Evaluating
Post-Mastectomy Chestwall and Regional Nodal XRT and
Post-Lumpectomy Regional Nodal XRT in Patients with
Positive Axillary Nodes Before Neoadjuvant Chemotherapy
Who Convert to Pathologically Negative Axillary Nodes After
Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)
USON 08079: A Phase III Trial Of Short Term Androgen
Deprivation With Pelvic Lymph Node Or Prostate Bed Only
Radiotherapy (SPORT) In Prostate Cancer Patients With A
Head and Neck Cancer
IMRT+/-Cetuximab H&N
USON 10025: A Phase III Study of Postoperative Radiation
Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected
Head and Neck Cancer (RTOG0920)
Rising Psa After Radical Prostatectomy (RTOG 0534)
Radiotherapy +/- Androgen Dep in Prost
USON 09200: A Phase III Prospective Randomized Trial
of Dose-Escalated Radiotherapy With or Without ShortTerm Androgen Deprivation Therapy for Patients With
Intermediate-Risk Prostate Cancer RTOG 0815
Glioblastoma
Standard vs High Dose XRT + Temozolomide in
Glioblastoma
Randomized Phase II Trial of Hypofractionated DoseEscalated Photon IMRT or Proton Beam Therapy Versus
Conventional Photon Irradiation with Concomitant and
Adjuvant Temozolomide in Patients with Newly Diagnosed
Glioblastoma
The US Oncology Network is supported by McKesson Specialty Health.
© 2015 McKesson Specialty Health. All rights reserved.